Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 16:58:101904.
doi: 10.1016/j.eclinm.2023.101904. eCollection 2023 Apr.

Data reproducibility issues on evidence synthesis of adverse events associated with HER2-targeted antibody-drug conjugates

Dan-Na Wu  1 , Ai-Jia Guan  2 , Guo-Fu Li  3   4
Affiliations

Data reproducibility issues on evidence synthesis of adverse events associated with HER2-targeted antibody-drug conjugates

Dan-Na Wu et al. EClinicalMedicine. .
No abstract available

Keywords: ADCs, antibody-drug conjugates; AEs, adverse events; HER2, human epidermal growth factor receptor 2; TEAEs, treatment-emergent adverse events.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests.

References

    1. Xu C., Yu T., Furuya-Kanamori L., et al. Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study. BMJ. 2022;377 - PMC - PubMed
    1. Fu Z., Liu J., Li S., et al. Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. eClinicalMedicine. 2022 - PMC - PubMed
    1. Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. - PMC - PubMed
    1. Thungappa S.C., Maksud T., Raut N., et al. Comparison of the efficacy, safety, pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, trastuzumab emtansine) with the kadcyla (trastuzumab emtansine) in the treatment of HER2-positive metastatic breast cancer: a randomized, open-label, multicenter study in India. Clin Breast Cancer. 2022;22(4):300–307. - PubMed
    1. Tolaney S.M., Tayob N., Dang C., et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol. 2021;39(21):2375–2385. - PubMed